Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy

• Autores: Brianna L. Norton, Matthew J. Akiyama, Philippe J. Zamor, Alan M. Litwin
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 32, Nº. 2, 2018 (Ejemplar dedicado a: Overcoming Barriers to Eliminate Hepatitis C), págs. 347-370
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Injection drug use is the most common transmission route for hepatitis C. High rates of infection are observed among individuals on opioid agonist therapy. Although people who inject drugs carry the highest burden, few have initiated treatment. We present a comprehensive review of the evidence on the efficacy of HCV medications, drug–drug interactions, and barriers to and models of care. Studies have demonstrated comparable efficacy for individuals who are on opioid agonist therapy compared with those who are not. We propose that a strategy of treatment and cure-as-prevention is imperative in this population to curb the hepatitis C epidemic.